CytoReason and Pfizer ink $110 million AI deal
CytoReason’s AI Earns Pfizer Extension Deal
CytoReason Announces Expanded Collaboration Deal with Pfizer
Data-crunching specialist CytoReason signs $110m Pfizer alliance
Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal
Pfizer to further tap CytoReason’s AI technology for drug discovery in up to $110M deal
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
The Next Chapter: Harnessing Big Data with Computational Disease Models
Bringing Data to Life – Joint Webinar about CytoReason-Ferring Collaboration
CytoReason expands reach in Asia, leveraging ML in drug development for Korean drugmakers
